key: cord-0427383-6nt6msrm
authors: Musser, J. M.; Christensen, P. A.; Olsen, R. J.; Long, S. W.; Subedi, S.; Davis, J. J.; Hodjat, P.; Walley, D. R.; Kinskey, J. C.; Gollihar, J. D.
title: Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas
date: 2021-07-22
journal: nan
DOI: 10.1101/2021.07.19.21260808
sha: 80649be3c93ba2c5e8a8a85d38d61f221803f965
doc_id: 427383
cord_uid: 6nt6msrm

Genetic variants of SARS-CoV-2 have repeatedly altered the course of the COVID-19 pandemic, and disease in individual patients. Delta variants (B.1.617.2, AY.2, and AY.3) are now the focus of international concern because they are causing widespread COVID-19 disease globally. Vaccine breakthrough cases caused by SARS-CoV-2 variants also are of considerable public health and medical concern worldwide. As part of a comprehensive project, we sequenced the genomes of 3,913 SARS-CoV-2 from patient samples acquired March 15, 2021 through July 3, 2021 in the Houston Methodist hospital system and studied vaccine breakthrough cases. During the study period Delta variants increased to cause 58% of all COVID-19 cases and spread throughout the metropolitan Houston area. In addition, Delta variants caused a significantly higher rate of vaccine breakthrough cases (19.7% compared to 5.8% for all other variants). Importantly, only 6.5% of all COVID-19 cases occurred in fully immunized individuals, and relatively few of these patients required hospitalization. Our genomic and epidemiologic data emphasize that vaccines used in the United States are highly effective in decreasing severe COVID-19 disease, hospitalizations, and deaths.

).

During the study period 213 patients were diagnosed with Delta variants, and 255 of the 3,913 patients (6.5%) met the CDC definition of vaccine breakthrough cases (Table 1A) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. There is a considerable lack of detailed information about patients in the United States with COVID-19 caused by Delta variants

. Compared to all other patients, there was no significant difference in median age, gender, admission rate, disease severity or hospital length of stay (Table 1A) . However, Delta cases were significantly more likely to be Asian (supporting multiple recent entry points) and less likely to be Hispanic or Latino, have significantly lower PCR cycle threshold (Ct) values (a proxy for higher virus . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.19.21260808 doi: medRxiv preprint load, a finding consistent with the reported increased transmissibility of Delta variants) on initial diagnosis, and cause a significantly higher rate of vaccine breakthrough cases (19.7% compared to 5.8% for all other variants) (Table 1A) .

We next examined metadata for the 255 vaccine breakthrough cases (Table 1B) .

Vaccinated patients had a significantly higher Ct, likely indicating lower virus load on initial diagnosis. A greater percentage of patients with Delta breakthrough cases was admitted to the hospital, but the number did not reach significance (Table 1B) .

Our genome sequence data document a very rapid increase of Delta variant cases in metropolitan Houston and a considerable corresponding decrease of COVID-19 cases caused by Alpha, findings similar to epidemiologic trends observed in the UK.

Delta was significantly more likely to cause a vaccine breakthrough case (Table 1A) .

However, importantly, only 6.5% of all COVID-19 cases occurred in fully immunized individuals, and relatively few of these patients required hospitalization. In the aggregate, our data add critical new information to the finding that these three vaccines are highly efficacious in decreasing severe COVID-19 disease, hospitalizations, and deaths.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.19.21260808 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.19.21260808 doi: medRxiv preprint Chi-square . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.19.21260808 doi: medRxiv preprint

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel

COVID-19 Vaccine Breakthrough Infections Reported to CDC -United States

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Trajectory of Growth of SARS-CoV-2 Variants